As Threat of Antibiotic Resistance Mounts, Biotechs Are Running Out of Cash and Time

Yusra Murad

September 25, 2019

Drugmakers working on new treatments seeking swift congressional, regulatory action to ease financial concerns

Greg Frank, the director of infectious disease policy at the Biotechnology Innovation Organization, said Achaogen’s fate sent a grave signal to companies in this space that are clamoring to prove their products’ success before cash runs out…

NPR

How the pandemic gave power to superbugs

Antibiotics cannot cure COVID. They don’t help a bit. And yet, new data shows that, during the pandemic, COVID patients…

The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.

The push for antibiotics to fight fast-evolving superbugs is snagging on a broken business model. Six startups have won Food and Drug…

Fighting AMR with a value and subscription model

The recent reintroduction of the Pasteur Bill seeks to address the global threat that antimicrobial-resistant (AMR) infections pose, one subscription…

Scientists use AI to find new antibiotics, but can they climb out of the ‘valley of death’ to the clinic?

Developing a new antibiotic can take as long as 15 years. But in as few as two, the target bug…

Name
First Last
Email
Zipcode
Organization
Title
Email
This field is for validation purposes and should be left unchanged.

Morning Consult

As Threat of Antibiotic Resistance Mounts, Biotechs Are Running Out of Cash and Time

Yusra Murad

September 25, 2019

Drugmakers working on new treatments seeking swift congressional, regulatory action to ease financial concerns

More

NPR

How the pandemic gave power to superbugs

Wall Street Journal

The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.

Pharmaceutical Technology

Fighting AMR with a value and subscription model

Fierce Biotech

Scientists use AI to find new antibiotics, but can they climb out of the ‘valley of death’ to the clinic?

Sign up for the latest on fighting AMR